Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC41H44ClF3N8O5 |
InChIKeyUZPKWEBZEBROEX-AYTRYJACSA-N |
CAS Registry3009849-06-0 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 23 Nov 2022 | |
| Neoplasms | Preclinical | China | 23 Nov 2022 |





